CO5680457A2 - Moleculas de union de nogo-a y uso farmaceutico de las mismas - Google Patents

Moleculas de union de nogo-a y uso farmaceutico de las mismas

Info

Publication number
CO5680457A2
CO5680457A2 CO06031001A CO06031001A CO5680457A2 CO 5680457 A2 CO5680457 A2 CO 5680457A2 CO 06031001 A CO06031001 A CO 06031001A CO 06031001 A CO06031001 A CO 06031001A CO 5680457 A2 CO5680457 A2 CO 5680457A2
Authority
CO
Colombia
Prior art keywords
nogo
same
pharmaceutical use
seq
union
Prior art date
Application number
CO06031001A
Other languages
English (en)
Inventor
Carmen Barske
Stefan Frentzel
Anis Khusro Mir
Martin E Schwab
Alessandra Vitaliti
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of CO5680457A2 publication Critical patent/CO5680457A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1.- Una molécula de unión que es capaz de unirse al polipéptido NogoA humano (SEC ID NO:5) o NiG humano (SEC ID NO:7) o NiG-D20 humano (SEC ID NO:24) o NogoA_342-357 humano (SEC ID NO:6) con una constante de disociación
CO06031001A 2003-09-19 2006-03-29 Moleculas de union de nogo-a y uso farmaceutico de las mismas CO5680457A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321997.9A GB0321997D0 (en) 2003-09-19 2003-09-19 Organic compound

Publications (1)

Publication Number Publication Date
CO5680457A2 true CO5680457A2 (es) 2006-09-29

Family

ID=29266310

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06031001A CO5680457A2 (es) 2003-09-19 2006-03-29 Moleculas de union de nogo-a y uso farmaceutico de las mismas

Country Status (25)

Country Link
US (2) US20090181023A1 (es)
EP (3) EP2423225A3 (es)
JP (1) JP2007527232A (es)
KR (1) KR20060119982A (es)
CN (1) CN1878792A (es)
AR (1) AR045671A1 (es)
AU (2) AU2004274164B2 (es)
BR (1) BRPI0414174B8 (es)
CA (1) CA2538725C (es)
CO (1) CO5680457A2 (es)
EC (1) ECSP066431A (es)
GB (1) GB0321997D0 (es)
IL (2) IL174145A (es)
IS (1) IS8404A (es)
MA (1) MA28088A1 (es)
MY (2) MY158078A (es)
NO (1) NO20061678L (es)
NZ (1) NZ545679A (es)
PE (1) PE20050949A1 (es)
RU (1) RU2380377C2 (es)
SG (1) SG146660A1 (es)
TN (1) TNSN06085A1 (es)
TW (1) TWI372060B (es)
WO (1) WO2005028508A2 (es)
ZA (1) ZA200601842B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
SG157418A1 (en) * 2004-12-01 2009-12-29 Univ Singapore Nogo a protein fragments as neuronal network- interacting peptides
AU2006265276B2 (en) * 2005-07-05 2011-10-13 Glaxo Group Limited Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体
CN114470197B (zh) * 2022-02-16 2023-10-03 天津长和生物技术有限公司 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990009438A1 (en) 1989-02-13 1990-08-23 Schering Aktiengesellschaft Berlin Und Bergkamen Novel thrombolytic
DK1098972T3 (da) * 1998-07-22 2011-01-03 Smithkline Beecham Ltd Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
ES2341842T3 (es) * 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
WO2003048083A2 (en) * 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
PL1711530T3 (pl) * 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych

Also Published As

Publication number Publication date
GB0321997D0 (en) 2003-10-22
WO2005028508A2 (en) 2005-03-31
MY161068A (en) 2017-04-14
AU2009200237A1 (en) 2009-02-12
BRPI0414174B1 (pt) 2019-06-04
BRPI0414174B8 (pt) 2021-05-25
CA2538725A1 (en) 2005-03-31
TNSN06085A1 (en) 2007-10-03
EP2248827A1 (en) 2010-11-10
NO20061678L (no) 2006-06-16
US20110008334A1 (en) 2011-01-13
IL174145A0 (en) 2006-08-01
MA28088A1 (fr) 2006-08-01
AU2009200237B2 (en) 2011-05-19
AU2004274164B2 (en) 2009-02-05
US20090181023A1 (en) 2009-07-16
EP2423225A2 (en) 2012-02-29
EP2423225A3 (en) 2013-03-20
AR045671A1 (es) 2005-11-02
CN1878792A (zh) 2006-12-13
CA2538725C (en) 2010-12-21
IL203007A (en) 2013-10-31
WO2005028508A3 (en) 2005-07-07
PE20050949A1 (es) 2005-12-16
ZA200601842B (en) 2007-09-26
BRPI0414174A (pt) 2006-10-31
ECSP066431A (es) 2006-09-18
IL174145A (en) 2010-11-30
RU2006112849A (ru) 2007-12-20
NZ545679A (en) 2009-11-27
MY158078A (en) 2016-08-30
IL203007A0 (en) 2011-08-01
JP2007527232A (ja) 2007-09-27
TW200517123A (en) 2005-06-01
EP1668033A2 (en) 2006-06-14
TWI372060B (en) 2012-09-11
KR20060119982A (ko) 2006-11-24
IS8404A (is) 2006-04-10
RU2380377C2 (ru) 2010-01-27
AU2004274164A1 (en) 2005-03-31
SG146660A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CO5680457A2 (es) Moleculas de union de nogo-a y uso farmaceutico de las mismas
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
ES2114786B1 (es) Tromboyetina. trombopoyetina recombinante y procedimiento de obtencion.
ES2139752T3 (es) Material cristalino poroso sintetico, mcm-58, su sintesis y uso.
EA200601753A1 (ru) Синтетические "мембранные якори"
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
NO974514D0 (no) Syntetisk HPV6/11 hydrud L1 DNA som koder for humant papillomavirus Type 11 L1-protein
BRPI0506148A (pt) preparação farmacêutica para o tratamento de choque
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
DE50309342D1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
DE602004002773D1 (de) Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon
BR0114977A (pt) segmentos preferidos de proteìna de filamento neural e métodos para uso dos mesmos
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
HUP0004605A1 (hu) Presenilinek és a béta-amiloid peptid vagy prekurzora közötti kölcsönhatás gátlására képes peptidek
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
BR0316544A (pt) Compostos calcilìticos
DE60132301D1 (de) Verwendung der extrazellulären Domäne von TRADE Molekülen in Medikamenten zur Behandlung von Neoplasie
Pongpairoj et al. Psoriasis, extradomain A+ fibronectin and the extracellular matrix.
UA91497C2 (ru) ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА
BR9608626A (pt) Peptédeo preparação farmacéutica e uso de um peptídeo
DE60113535D1 (de) Kompositionen und verwendungen von cgi-69
DE60115039D1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität

Legal Events

Date Code Title Description
FG Application granted